325457-61-2

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-[4-nitro-2-(trifluoromethyl)phenoxy]-, 1,1-dimethylethyl ester
• CAS NO: 325457-61-2
• Molecular Formula: C17H21F3N2O5
• Molecular Weight: 390.359
• Mol File: 325457-61-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-[4-nitro-2-(trifluoromethyl)phenoxy]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-[4-nitro-2-(trifluoromethyl)phenoxy]-, 1,1-dimethylethyl ester(325457-61-2)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-[4-nitro-2-(trifluoromethyl)phenoxy]-, 1,1-dimethylethyl ester(325457-61-2)

Safety Data

• Hazardous Substances Data: 325457-61-2(Hazardous Substances Data)

Usage

Classification

Ester derivative of piperidinecarboxylic acid
It is derived from piperidinecarboxylic acid and contains an ester functional group.

Functional groups

4-nitro-2-(trifluoromethyl)phenoxy
A nitro group is attached to a phenyl ring, which in turn is connected to a trifluoromethyl group and an ester group.

Usage

Pharmaceutical industry as a building block or intermediate
Commonly used in the synthesis of various drugs and pharmacologically active compounds.

Contribution to drug molecules

Effectiveness and specific targeting of biological pathways
Its chemical structure and properties make it suitable for incorporation into drug molecules, enhancing their effectiveness or targeting specific biological pathways.

Potential applications

Drug discovery and development
Further research and exploration of this compound may reveal its significance in the medical field.

Upstream product

• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 1548-61-4 4-nitro-2-(trifluoromethyl)phenol 

Downstream Products

• 325457-62-3 4-[(N-(t-butoxycarbonyl)piperidin-4-yl)oxy]-3-trifluoromethylbenzenamine 
• 405887-82-3 C₂₁H₃₁F₃N₂O₅Si 
• 405887-83-4 C₂₁H₃₁F₃N₂O₅Si 

Relevant articles and documents

Cinnamyl derivatives: Synthesis and factor Xa (FXa) inhibitory activities

To develop a potent and oral anticoagulant, a series of compounds with cinnamyl moiety was synthesized and their factor Xa (FXa) inhibitory activities were examined. As a result, some cinnamyl derivatives showed potent FXa inhibitory activities in vitro. Among them, compounds with substituent at the 3-position on the central benzene ring represented by (N-{4-[1-(acetimidoyl) piperidin-4-yloxy]-3-chlorophenyl}-N-[(E)-3-(3-amidinophenyl)-2-propenyl] sulfamoyl)acetic acid dihydrochloride (45b) and (N-{4-[1-(acetimidoyl)piperidin- 4-yloxy]-3-carbamoylphenyl}-N-[(E)-3-(3-amidinophenyl)-2-propenyl]sulfamoyl) acetic acid dihydrochloride (45j) exhibited potent FXa inhibitory activities with IC50 values of less than 10 nM in vitro. These compounds also showed potent anticoagulant activities both in vitro and ex vivo. Furthermore, these compounds exhibited no lethal toxicity (30 mg/kg, i.v.).

BISARYLUREA DERIVATIVES

The present invention relates to bisarylurea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

BENZAMIDINE DERIVATIVES

Benzamidine derivatives of formula (I) or pharmaceutically acceptable salts thereof exhibit excellent inhibitory activity against factor Xa and are useful for treating or preventing blood coagulation disorders: wherein R 1represents a hydrogen atom, a halogen atom, an alkyl group or a hydroxyl group; R 2represents a hydrogen atom, a halogen atom or an alkyl group, R 3represents a hydrogen atom, an optionally substituted alkyl group, an aralkyl group, an optionally substituted alkanoyl group or an optionally substituted alkylsulfonyl group, R 4and R 5 are the same as or different from each other and each represent a hydrogen atom, a halogen atom, an optionally substituted alkyl group, an alkoxy group, a carboxyl group, an alkoxycarbonyl group or an optionally substituted carbamoyl group, and R 6represents a substituted pyrrolidine group or substituted piperidine group.